Gothenburg, October 24, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary commercially available technology platform iTANK, announced today that the last patient has been enrolled in the clinical phase I/II study evaluating the company’s oncolytic drug candidate ELC-100 (AdVince) against neuroendocrine tumors. The study’s preliminary results are expected to be reported in the first half of 2025.
The study, which is sponsored by Uppsala University, is carried out in two stages – a dose escalation study and a dose expansion study. The ongoing, first, dose escalation study primarily aims to evaluate the safety of the treatment in patients and identify the maximum tolerated dose (MTD). During the study, four dose levels are evaluated in three patients each. In addition to the primary goal of the dose escalation study, efficacy is also evaluated, for example the form of tumor response.
The twelfth and last patient of the study has now been enrolled and initiated treatment. The preliminary study results are expected to be presented during the first half of 2025. Based on the outcome of the dose escalation study and subsequent outcome of discussions with regulatory authorities, the company will formulate a strategy for the continued clinical development of ELC-100.
“We have now enrolled the last patient in the dose-escalation stage of our phase I/II clinical trial with ELC-100 in patients affected by neuroendocrine tumors. The unique treatment is based on a virus that has a natural ability to infect and kill cancer cells. We look forward to presenting the results of the first phase of the study and evaluating the next step in our clinical development of ELC-100,” said Jamal El-Mosleh, CEO of Elicera Therapeutics.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Advisor
Mangold Fondkommission AB
About ELC-100
Elicera’s oncolytic virus treatment ELC-100 is a genetically modified virus with the ability to selectively infect, multiply in, and kill neuroendocrine cancer cells but not healthy cells. The company’s ongoing clinical phase I/II study is fully funded by VictoryNET-Foundation.
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immune-oncology treatments based on iTANK-armed oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand’s research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. The iTANK-technology platform can be used to arm any CAR T-cell therapy in development and activate killer T-cells against cancer. The company addresses an international billion-dollar market in cell therapy development by offering out-licensing of iTANK to CAR T-cell players in the pharmaceutical industry. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit www.elicera.com
